Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies  by Clark, David E. et al.
Bioorganic & Medicinal Chemistry Letters 26 (2016) 2920–2926Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier .com/ locate/bmclApplication of virtual screening to the discovery of novel
nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with
potential for the treatment of cancer and axonopathieshttp://dx.doi.org/10.1016/j.bmcl.2016.04.039
0960-894X/ 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author. Tel.: +44 (0) 1279 645 611; fax: +44 (0) 1279 645 646.
E-mail address: david.clark@crl.com (D.E. Clark).
y Current address: Drug Discovery Unit, Cancer Research UK Manchester Institute,
The University of Manchester, Wilmslow Road, Manchester M20 4BX, United
Kingdom.
 Current address: John van Geest Centre for Brain Repair, Department of Clinical
Neurosciences, University of Cambridge, Robinson Way, Cambridge CB2 0PY, United
Kingdom.David E. Clark a,⇑, Bohdan Waszkowycz a,y, Melanie Wong a, Peter M. Lockey a, Robert Adalbert c,,
Jonathan Gilley c,, Jonathan Clark b, Michael P. Coleman c,
aCharles River Laboratories, 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom
bBabraham Bioscience Technologies Ltd, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
c The Babraham Institute, Babraham Research Campus, Babraham, Cambridge CB22 3AT, United Kingdoma r t i c l e i n f o
Article history:
Received 2 February 2016
Revised 14 April 2016
Accepted 15 April 2016
Available online 16 April 2016
Keywords:
NAMPT
Virtual screening
Axon degeneration
Molecular docking
Similarity searchinga b s t r a c t
NAMPT may represent a novel target for drug discovery in various therapeutic areas, including oncology
and inflammation. Additionally, recent work has suggested that targeting NAMPT has potential in treat-
ing axon degeneration. In this work, publicly available X-ray co-crystal structures of NAMPT and the
structures of two known NAMPT inhibitors were used as the basis for a structure- and ligand-based vir-
tual screening campaign. From this, two novel series of NAMPT inhibitors were identified, one of which
showed a statistically significant protective effect when tested in a cellular model of axon degeneration.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Previously identified as a cytokine (pre-B-cell colony enhancing
factor, PBEF) and also claimed as an insulin-mimetic hormone (vis-
fatin), nicotinamide phosphoribosyltransferase (NAMPT) converts
nicotinamide to nicotinamide mononucleotide (NMN), which is a
key nicotinamide adenine dinucleotide (NAD) intermediate.
NAMPT is currently of much interest in a number of fields of
research, including NAD biology, metabolism and inflammation.1,2
NAMPT activity has been shown to be essential for maintaining
adequate intracellular NAD levels, suggesting that it may play a
central role in modulating the activity of a wide range of NAD-
dependent enzymes. By regulating NAD availability, NAMPT is able
to control both cell viability and the inflammatory response. For
instance, tumor cells develop dependence on NAMPT due to their
increased energy requirements and the elevated activity of NAD-
consuming enzymes such as the sirtuins and poly(ADP-ribose)
polymerases.3 NAMPT may thus represent a novel target for drugdiscovery in various therapeutic areas, including oncology and
inflammation2,4 and, as a consequence, there has been a great deal
of research effort by the medicinal chemistry community seeking
novel inhibitors of the target.5
In addition, recent work has suggested that targeting NAMPT
may also be beneficial in treating axon degeneration.6 The subse-
quent enzyme in the NAD salvage pathway, NMNAT, greatly delays
axon degeneration in injury and some disease models when a
stable isoform is targeted to axons.7–9 Axon degeneration is an
early feature of many neurodegenerative diseases and needs to
be prevented for treatments to be effective. NAMPT inhibitors
FK866 and CHS828 both phenocopy the protective effect of
NMNAT when applied at the time of, or subsequent to, axonal tran-
section.6,10,11 This suggests that accumulation of the NMNAT sub-
strate (and NAMPT product) NMN within axons is at least partly
responsible for their degeneration after endogenous axonal
NMNAT is degraded, potentially in addition to depletion of axonal
NAD. As many established cancer chemotherapeutics are toxic to
axons,12 NAMPT inhibition offers the attractive possibility of con-
tributing to cancer treatment while simultaneously preserving
axons during a regime of chemotherapy. Here, we report the iden-
tification of novel, small molecule inhibitors of NAMPT for axono-
pathies, and potentially other indications, by means of a virtual
screening campaign using structure- and ligand-based techniques.
Figure 3. The five-point common pharmacophore query derived from FK
Figure 1. X-ray structure (left) and schematic ligand interaction diagram (right) of FK866 bound to NAMPT showing water molecules that mediate contacts between the
ligand and protein.
Figure 2. Details of the binding interactions of FK866 in PDB structure 2GVJ
showing the aromatic stacking (Phe193, Tyr18B) around the pyridine-vinyl head
group.
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Chemical structures of known NAMPT inhibitors used as queries for ligand-based
virtual screening
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D. E. Clark et al. / Bioorg. Med. Chem. Lett. 26 (2016) 2920–2926 2921The structure-based virtual screen (SBVS) employed the pub-
licly available X-ray crystal structures of NAMPT in complex with
FK866 (PDB code: 2GVJ) and nicotinamide mononucleotide
(NMN, PDB code: 2GVG). The binding interactions of FK866 are
depicted in Figure 1.
Although FK866 occupies a relatively extended binding site,
there is only one direct hydrogen bond to the enzyme (to
Ser275) and two water-mediated hydrogen bonds (to Asp219
and Wat242 via Wat645). The X-ray structure also shows a water
molecule within hydrogen-bonding distance of the pyridine group.
Figure 2 shows in more detail the close aromatic stacking of the
pyridine-vinyl head group between Phe193 and Tyr18B. In con-
trast, the benzoyl-piperidine tail is more loosely bound, with the
phenyl ring occupying a small pocket bounded by the side chains
of Lys189 and Arg349.
The Glide program13 was used to dock various datasets of
commercially available compounds into the active site of NAMPT.
These compound sets had been pre-filtered using molecular
property (e.g., 250 6MW 6 450, 0.5 6 C logP 6 4.0 and866 (green carbon atoms) and MPI-0479626 (orange carbon atoms).
Figure 4. The E-pharmacophore query generated from the 2GVJ X-ray structure.
Excluded volumes are shown in yellow.
Table 2
Summary of ligand-based virtual screening results
Search type Number of hits selected
2D substructure 94
2D similarity 79
3D pharmacophore 95
3D similarity 153
E-pharmacophore 72
Table 3
Breakdown of activities for the 40 compounds for which IC50 values were determined
Activity range Number of compounds
100 nM 6 IC50 < 1 lM 5
1 lM 6 IC50 < 10 lM 15
IC50P 10 lM 20
2922 D. E. Clark et al. / Bioorg. Med. Chem. Lett. 26 (2016) 2920–2926TPSA 6 120 Å2) and substructural criteria14 to remove non-drug-
like molecules. In the interests of generating the most diverse
results possible in a timely manner, it was decided to run the fol-
lowing docking screens:Table 4
Chemical structures, IC50 values and provenance for selected hits identified by the first ro
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O SBVS1—as the most conservative approach to finding close ana-
logues of FK866, a 46,000-compound dataset of meta-pyridine-
containing structures was docked against the 2GVJ structure
including both Wat645 and Wat1339; the latter water helps
compounds to achieve an FK866-like binding of the pyridine
group;
 SBVS2—as a more open-ended screen, a larger, more diverse
dataset of 750,000 compounds was docked to the 2GVJ structure
including only Wat645. Removal of Wat1339 enables more
diverse chemotypes to bind to the pyridine subsite;
 SBVS3—to encourage more diversity in ligand binding, the larger
dataset was docked to the 2GVG structure containing no waters.
Although 2GVG is very similar to 2GVJ, small changes in amino
acid side chain positions can sometimes influence the docking
results and yield different solutions. Removal of Wat645 also
allows for larger amide mimics to bridge between Ser275 and
Asp219.
For SBVS1, the Glide SP protocol was used to dock themeta-pyr-
idine dataset, constraining at least one hydrogen bond to either
Ser275 or Wat645, on the basis that compounds forming neitherund of virtual screening
NAMPT IC50 (lM) Provenance
0.22 SBVS
0.32 LBVS
0.67 SBVS
0.78 LBVS
0.94 LBVS
1.9 LBVS
3.2 LBVS
3.8 SBVS
5.0 LBVS
Table 5
2D substructural queries used for follow-up searches
2D substructure query Purpose
N
O
N
H
Search for a linker not seen in round
1 hits. In this and other queries
containing a pyridine ring, no
substitution was permitted on the
pyridine ring
X
X
X
N X=C,N
Search for a novel head-group and/or
linker. In these searches, the atoms
marked ‘X’ were allowed to be either
carbon or nitrogen
N
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N
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N
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N F Search for other compounds
containing this tail-group (from
compound 9) but with other head-
groups
N
H
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N N
N
Search for other compounds
containing this tail-group (from
compound 5) but with other head-
groups
S
N
H
O O
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N
This query used the Daylight
SMARTS ‘.’ convention to specify that
a biaryl sulfonamide (as seen in
compound 8) should be present in
addition to a meta-substituted
pyridine, but did not specify how the
two moieties should be linked. In the
biaryl fragment part of the query, all
the aromatic atoms were set to atom
type ‘a’ to allow them to match any
aromatic atom
N N
H
O
N
N
N
O
Search for other compounds
containing this fragment (observed
in compound 4) which lacks the
unwanted alpha–beta unsaturated
carbonyl in the linker
Table 6
Breakdown of activities for the 41 compounds for which IC50 values were determined
Activity range Number of compounds
IC50 < 100 nM 4
100 nM 6 IC50 < 1 lM 9
1 lM 6 IC50 < 10 lM 8
IC50P 10 lM 20
D. E. Clark et al. / Bioorg. Med. Chem. Lett. 26 (2016) 2920–2926 2923of the amide hydrogen bonds would not be very plausible ligands.
For SBVS2 and SBVS3, the 750K-compound dataset was too large
for docking with Glide SP in a reasonable timeframe. Therefore,
the dataset was docked with the faster Glide HTVS protocol and
the top-scoring 50,000 solutions were re-docked using Glide SP.
Hydrogen bond constraints to Ser275 or Wat645 (if present) were
added as before. Default Glide docking parameters were applied,
with the post-docking geometry minimization stage (and incorpo-
ration of estimated strain energy into the docking score) included
for the Glide SP jobs. One pose per input ligand was retained, and
a maximum of 30,000 solutions per SP docking run retained for
analysis.
The analysis of the docked compounds from each of the docking
screens involved using the Maestro graphical interface to search
for compounds of interest based on a combination of binding fea-
tures and docking score, and manual visualization of sets of a few
thousand docked ligands. Analysis was further facilitated by parti-
tioning the ligands into molecular weight bins, so that a balanced
selection could be made across different molecular weight ranges.
The analysis resulted in a set of 630 compounds for consideration
(221 from SBVS1, 276 from SBVS2, and 133 from SBVS3).
As a complement to the structure-based campaign described
above, a ligand-based strategy was also pursued. An assessment
of the known ligands for NAMPT suggested that the compounds fell
into two broad classes: those with long aliphatic linkers and those
with a phenyl ring in the linker. It was decided to carry out ligand-
based virtual screening (LBVS) with a representative of each of
these classes and so MPI-04796263 (1) and FK866 (2) (Table 1)
were selected as query ligands.
Multiple 2D and 3D ligand-based searches were undertaken
using these query compounds. The 2D searches utilized a database
of 2.35 million commercially available compounds while the 3D
searches were run against the 750,000-compound database men-
tioned earlier. In brief, the following searches were carried out:
 2D substructure—given the presence of a terminal meta-pyridine
in both query ligands plus a knowledge of this moiety’s binding
mode in the NAMPT active site, it was decided to search for com-
pounds that possessed this group connected by a two-atom lin-
ker to a carbonyl group. These searches were carried out using
Daylight15 SMARTS queries.
 2D fingerprint—several similarity searches were carried out
around the two compounds using Daylight15 fingerprints and
12 different fingerprint types available within Canvas.16
 3D pharmacophore—3D pharmacophores were derived and
searched for using Phase.17 Query pharmacophores were based
on the individual compounds and an additional common phar-
macophore was derived (Fig. 3).
 3D shape similarity—Phase Shape18 was used to carry out 3D sim-
ilarity searches based on the two query ligands. Initial experi-
ments with FK866 revealed that it was difficult to find good
matches to the whole ligand and particularly for the key termi-
nal pyridine moiety. Therefore, the search database was changed
to use just a focused set of 8000 terminalmeta-pyridines iden-
tified in the 2D substructure searches mentioned above.
 E-pharmacophore—this method19 combines pharmacophore per-
ception with protein–ligand energetic terms computed by the
Glide XP scoring function to rank the importance of pharma-
cophore features. It was applied to the FK866:NAMPT co-crystal
structure (2GVJ). The result was a seven-feature pharmacophore
together with a set of excluded volume spheres denoting the
steric boundaries of the NAMPT active site (Fig. 4).
The results of all the ligand-based searches are summarized in
Table 2. Overall, 493 compounds were selected from all thesearches. When duplicates were removed from this list, a final
set of 417 unique compounds remained.
Combining the 630 unique hits obtained from the structure-
based virtual screening with the 417 from the ligand-based cam-
paign gave a total of 1047 compounds. When duplicates were
removed, 1028 compounds remained, indicating a very small over-
lap between the hits selected by the two types of virtual screen.
This set of 1028 compounds represents a diverse collection of
potential NAMPT inhibitors. This fact was demonstrated by cluster-
ing the set (using Daylight15 fingerprints, Ward’s clustering
method20 and a Tanimoto similarity threshold of 0.85), an opera-
tion that resulted in 878 clusters.
After review by a medicinal chemist taking into account
(subjective) criteria such as chemical tractability and apparent
Table 7
Chemical structures, IC50 values and key calculated properties for the most potent examples of the two series identified by the second round of virtual screening
Compound Series Structure IC50 (nM) MW, TPSA (Å2), C logP, LE, LLE
12 Cyclopropyl
NHO
N
41.8 294.4, 42.0, 3.85, 0.46, 3.49
13 Pyrazole
N
NNH
O
N
N
242.7 423.5, 65.1, 3.15, 0.28, 2.79
Compound 12 is assumed to be a mixture of four stereoisomers. Physicochemical properties were calculated using Advanced Chemistry Development, Inc.’s Percepta
program.22
Table 8
Plasma protein binding and CYP inhibition data
Compound
number
Human
plasma
protein
binding (%
bound)
CYP1A2%
inhib. @
3 lM
CYP2C9%
Inhib. @
3 lM
CYP2D6%
Inhib. @
3 lM
CYP3A4%
Inhib. @
3 lM
12 99.2 22 31 1 63
13 99.6 23 43 3 20
2924 D. E. Clark et al. / Bioorg. Med. Chem. Lett. 26 (2016) 2920–2926similarities to and differences from known NAMPT inhibitors, it
was decided to order 102 compounds from the appropriate com-
mercial vendors. 99 of the 102 compounds were received and of
these, 42 showed 50% inhibition or greater when screened in the
primary assay21 at 100 lM in singlet. 40 compounds were con-
firmed to be hits when retested in duplicate at 100 lM and IC50
values were determined for these. A breakdown of the distribution
of the resulting IC50 values is shown in Table 3.
The five sub-micromolar compounds are shown in Table 4,
along with some other compounds in the single-digit micromolar
range that contain potentially novel structural features in the con-
text of NAMPT inhibitors, e.g., in terms of the nature of the linker
moiety to the terminal meta-pyridine. It is noteworthy that both
structure- and ligand-based techniques contributed to this set of
hits underlining the value of carrying out both types of search.
In a second round of virtual screening, multiple 2D substructure
and similarity searches were carried out seeking, in particular, ana-
logues lacking the potentially problematic alpha–beta unsaturatedTable 9
Microsomal stability and Caco-2 permeability data. Microsomal stability data reflect% of p
Compound
number
Microsomal stability
(human, + NADPH)
Microsomal stability
(human,  NADPH)
Micro
(mous
12 7 96 43
13 63 104 19carbonyl group. Specifically, 2D similarity searches were carried
out using hit compounds 3, 4, 10 and 11 as queries and a set of
eight 2D substructure searches using the queries shown in Table 5.
These queries were intended to follow-up on interesting structural
features observed in the first round hits and to try to find alterna-
tives to the meta-pyridine as well as additional linker groups. All
searches were carried out using the previously mentioned data-
base of 2.35 million commercially available compounds.
This effort led to the purchase and testing of an additional 79
compounds. 41 of these went on to have IC50 values determined.
A breakdown of the activities of these 41 compounds is provided
in Table 6. The most active compound discovered in this second
round of screening showed an IC50 value of 41.8 nM.
Reviewing these results led to the identification of two distinct
series both lacking the alpha–beta unsaturated carbonyl group. The
most active example of each series is shown in Table 6 along with
some key calculated properties. Fresh solid samples of the two
compounds were obtained and submitted for analytical testing
(LC/MS and NMR). For both compounds, the observed 1H NMR
spectrum was consistent with the structure shown in Table 7
and the purities were acceptable (93% and 99% for 12 and 13,
respectively).
The two heads of series were also profiled in a panel of in vitro
ADME assays to identify liabilities that would need to be addressed
during hit-to-lead optimization. The results of these tests are
shown in Tables 8 and 9.
The data show that both compounds are highly protein bound
and there are potential CYP450 liabilities that would need to be
dealt with during hit-to-lead optimization. Compound 13 showsarent compound remaining at 30 min, with the compounds being tested at 5 lM
somal stability
e, + NADPH)
Microsomal stability
(mouse,  NADPH)
Caco-2
permeability  106 cm/
s
87 <70% recovery
96 <70% recovery
Figure 5. Compound 13 delays degeneration of injured axons in a cellular assay.
D. E. Clark et al. / Bioorg. Med. Chem. Lett. 26 (2016) 2920–2926 2925moderate stability in the presence of human and mouse liver
microsomes (with co-factor) but 12 appears particularly vulnera-
ble to metabolism by human microsomes. In terms of Caco-2 per-
meability, the results for both compounds were affected by low
recovery, but the experiments (and in silico calculations22) sug-
gested that the compounds would be highly permeable.
A cellular assay for axon survival was established and used to
test the two heads of series (compounds 12 and 13). SuperiorFigure 6. Comparison of DMSO-treated (control) axons with those treated with 100cervical ganglion explant cultures from neonatal mice were treated
with each test compound less than 10 min before axons were tran-
sected using a microscalpel. Images were captured by phase con-
trast microscopy and degeneration index calculated as previously
described.6 Compound 13 administered at 1 lM protected injured
axons significantly at 8 h after cut (Fig. 5).
Figure 6 shows a comparison of the effect on transected axons
of 100 nM FK866 and 1 lM 13 with a control (DMSO). Qualita-
tively, it can be seen that the DMSO treated axons degenerate fas-
ter over time than axons treated with either of the compounds.
While the protection afforded by 13 in this assay was less pro-
longed than that obtained with the more potent FK866,6 this result
is nonetheless encouraging for an unoptimised compound and
demonstrates the effectiveness of our virtual screening strategy
in identifying molecules with the desired biological effect.
At the time this work was completed (late 2012), to the best of
our knowledge neither of the chemotypes discovered had been
reported in the context of NAMPT inhibition. More recently,
Genentech and Forma have published a paper23 describing cyclo-
propyl-linked NAMPT inhibitors discovered using fragment-based
screening. The highlighted example from the publication is shown
in Table 10 with associated in vitro biochemical data. Following
in vitro ADME profiling, compound 14 was orally dosed to nude
mice (10 mg/kg b.i.d.) and displayed good plasma exposures over
a 24 h period with free concentrations constantly exceeding the
cellular anti-proliferation IC50 values. Subsequently, the compound
also showed strong efficacy in an HT-1080 fibrosarcoma xenograft
model when orally administered for five days to tumor-bearingnM FK866 and 1 lM of compound 13 at time of cut, and 8 h and 24 h post-cut.
Table 10
Example compounds from Refs. 16,17 having similar structures to the series discovered in this work
Compound number Structure NAMPT IC50 (nM) Cellular IC50 (nM)
14
N N
H
O
S
O O
N
N
5.1 1.3 ± 0.2 (HT-1080)
15
N
N
H
N
N
H
O S
O O
43 >10,000 (A2780)
2926 D. E. Clark et al. / Bioorg. Med. Chem. Lett. 26 (2016) 2920–2926nude mice using the same dosing regimen. Furthermore, the
observed anti-tumor effects were achieved with minimal impact
on the mouse body weights.23 Coincidentally, the same companies
also published a compound similar to our pyrazole-linked example
in a slightly earlier (but still post-2012) paper24 (15, Table 10)
describing a structure-based design approach to NAMPT inhibitor
discovery. Interestingly, the sulfone element in both compounds
is reminiscent of the sulfonamide seen in 8 (Table 4).
In conclusion, we have described a structure- and ligand-based
virtual screen that resulted in the rapid and cost-effective discov-
ery of two series of NAMPT inhibitors that were novel in that con-
text at the time of their discovery and had good potential for
further optimization (although, for commercial reasons, this was
never pursued). The subsequent publications from other groups
reporting similar compounds bears out the effectiveness of the
strategy employed. Encouragingly, one of the hits from the virtual
screen showed a statistically significant protective effect when
tested in a cellular model of axon degeneration adding weight to
the hypothesis6 that small molecule inhibition of NAMPT may be
a fruitful approach to the treatment of neurodegenerative diseases.
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